Our Mission

To discover novel therapeutics that will stop the progression
of neurodegenerative diseases by targeting their underlying causes.

Our Programs


UCB0599 Phase 1b in PD Patients


Neuropore Receives a Grant from The ALS Association

February 17, 2020

Neuropore Therapies, Inc., a clinical stage biopharmaceutical company announced today that it has been awarded a grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist for the treatment of amyotrophic lateral sclerosis.

See All News

NPT® Publications

Neuropore publishes paper describing preclinical in vivo characterization of  small molecule targeting α-synuclein as a potential Parkinson's disease therapeutic
November 2nd, 2018

Report in Scientific Reports, describes the beneficial effects of NPT200-11 on multiple disease relevant endpoints in a transgenic mouse model of Parkinson's disease.

See All Publications



A team poised for success

About Our Team

Our Partners


UCB Logo

Foundations & Academic InstitutionsSEE ALL

The Michael J. Fox Foundation for Parkinson's Research
Albert Einstein College of Medicine
University of Sydney

Connect with Neuropore